Ibotenic acid and thioibotenic acid:: a remarkable difference in activity at group III metabotropic glutamate receptors

被引:45
作者
Hermit, MB
Greenwood, JR
Nielsen, B
Bunch, L
Jorgensen, CG
Vestergaard, HT
Stensbol, TB
Sanchez, C
Krogsgaard-Larsen, P
Madsen, U
Bräuner-Osborne, H
机构
[1] Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] Danish Univ Pharmaceut Sci, Dept Pharmacol, DK-2100 Copenhagen, Denmark
[3] H Lundbeck & Co AS, Dept Mol Pharmacol, Div Biol Res, DK-2500 Copenhagen, Denmark
[4] H Lundbeck & Co AS, Dept Neuropharmacol Res, Div Biol Res, DK-2500 Copenhagen, Denmark
关键词
ibotenic acid; thioibotenic acid; glutamate receptor; mGlu receptor; group III agonist; docking; homology model; conformational energy;
D O I
10.1016/j.ejphar.2003.12.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, we have determined and compared the pharmacological profiles of ibotenic acid and its isothiazole analogue thioibotenic acid at native rat ionotropic glutamate (iGlu) receptors and at recombinant rat metabotropic glutamate (mGlu) receptors expressed in mammalian cell lines. Thioibotenic acid has a distinct pharmacological profile at group III mGlu receptors compared with the closely structurally related ibotenic acid; the former is a potent (low mum) agonist, whereas the latter is inactive. By comparing the conformational energy profiles of ibotenic and thioibotenic acid with the conformations preferred by the ligands upon docking to mGlu(1) and models of the other mGlu subtypes, we propose that unlike other subtypes, group III mGlu receptor binding sites require a ligand conformation at an energy level which is prohibitively expensive for ibotenic acid, but not for thioibotenic acid. These studies demonstrate how subtle differences in chemical structures can result in profound differences in pharmacological activity. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:241 / 250
页数:10
相关论文
共 60 条
  • [51] MOTULSKY H, 1997, CURRENT PROTOCOLS NE
  • [52] MOLECULAR DIVERSITY OF GLUTAMATE RECEPTORS AND IMPLICATIONS FOR BRAIN-FUNCTION
    NAKANISHI, S
    [J]. SCIENCE, 1992, 258 (5082) : 597 - 603
  • [53] Pharmacological profiles of the metabotropic glutamate receptor ligands [3H]L-AP4 and [3H]CPPG
    Naples, MA
    Hampson, DR
    [J]. NEUROPHARMACOLOGY, 2001, 40 (02) : 170 - 177
  • [54] Pagano A, 2001, J NEUROSCI, V21, P1189
  • [55] COOPERATIVE MODULATION OF [H-3] MK-801 BINDING TO THE N-METHYL-D-ASPARTATE RECEPTOR-ION CHANNEL COMPLEX BY L-GLUTAMATE, GLYCINE, AND POLYAMINES
    RANSOM, RW
    STEC, NL
    [J]. JOURNAL OF NEUROCHEMISTRY, 1988, 51 (03) : 830 - 836
  • [56] Protein structure computing in the genomic era
    Schwede, T
    Diemand, A
    Guex, N
    Peitsch, MC
    [J]. RESEARCH IN MICROBIOLOGY, 2000, 151 (02) : 107 - 112
  • [57] [H-3] CGP-39653 - A NEW N-METHYL-D-ASPARTATE ANTAGONIST RADIOLIGAND WITH LOW NANOMOLAR AFFINITY IN RAT-BRAIN
    SILLS, MA
    FAGG, G
    POZZA, M
    ANGST, C
    BRUNDISH, DE
    HURT, SD
    WILUSZ, EJ
    WILLIAMS, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 192 (01) : 19 - 24
  • [58] A FAMILY OF METABOTROPIC GLUTAMATE RECEPTORS
    TANABE, Y
    MASU, M
    ISHII, T
    SHIGEMOTO, R
    NAKANISHI, S
    [J]. NEURON, 1992, 8 (01) : 169 - 179
  • [59] TANABE Y, 1993, J NEUROSCI, V13, P1372
  • [60] TURNER JJ, 1992, BEHAV PHARMACOL, V3, P359